{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T07:35:41Z","timestamp":1776497741544,"version":"3.51.2"},"reference-count":33,"publisher":"Japanese Circulation Society","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Circ J"],"published-print":{"date-parts":[[2016]]},"DOI":"10.1253\/circj.cj-16-0266","type":"journal-article","created":{"date-parts":[[2016,4,8]],"date-time":"2016-04-08T12:13:59Z","timestamp":1460117639000},"page":"1067-1072","source":"Crossref","is-referenced-by-count":51,"title":["Future of the Prevention and Treatment of Coronary Artery Disease"],"prefix":"10.1253","volume":"80","author":[{"given":"Philippe Gabriel","family":"Steg","sequence":"first","affiliation":[{"name":"French Alliance for Cardiovascular clinical Trials (FACT), and Universit\u00e9 Paris-Diderot, INSERM U-1148, Bichat Hospital, Fibrosis, Inflammation and Remodeling (FIRE) Department, Assistance Publique-H\u00f4pitaux de Paris"},{"name":"National Heart and Lung Institute, Institute of Cardiovascular Medicine and Science, Royal Brompton Hospital, Imperial College"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gr\u00e9gory","family":"Ducrocq","sequence":"additional","affiliation":[{"name":"French Alliance for Cardiovascular clinical Trials (FACT), and Universit\u00e9 Paris-Diderot, INSERM U-1148, Bichat Hospital, Fibrosis, Inflammation and Remodeling (FIRE) Department, Assistance Publique-H\u00f4pitaux de Paris"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"330","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Tunstall-Pedoe H, Kuulasmaa K, M\u00e4h\u00f6nen M, Tolonen H, Ruokokoski E, Amouyel P. Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA project populations: Monitoring trends and determinants in cardiovascular disease. <i>Lancet<\/i> 1999; 353: 1547\u20131557.","DOI":"10.1016\/S0140-6736(99)04021-0"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Ford ES, Ajani UA, Croft JB, Critchley JA, Labarthe DR, Kottke TE, et al. Explaining the decrease in U.S. deaths from coronary disease, 1980\u20132000. <i>N Engl J Med<\/i> 2007; 356: 2388\u20132983.","DOI":"10.1056\/NEJMsa053935"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, et al; European Association for Cardiovascular Prevention &amp; Rehabilitation (EACPR); ESC Committee for Practice Guidelines (CPG): European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). <i>Eur Heart J<\/i> 2012; 33: 1635\u20131701.","DOI":"10.1093\/eurheartj\/ehs092"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Task Force Members;Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, Budaj A, et al. 2013 ESC guidelines on the management of stable coronary artery disease: The Task Force on the management of stable coronary artery disease of the European Society of Cardiology. <i>Eur Heart J<\/i> 2013; 34: 2949\u20133003.","DOI":"10.1093\/eurheartj\/eht296"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Bangalore S, Bhatt DL, Steg PG, Weber MA, Boden WE, Hamm CW, et al. \u03b2-blockers and cardiovascular events in patients with and without myocardial infarction: Post hoc analysis from the CHARISMA trial. <i>Circ Cardiovasc Qual Outcomes<\/i> 2014; 7: 872\u2013881.","DOI":"10.1161\/CIRCOUTCOMES.114.001073"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Bangalore S, Steg G, Deedwania P, Crowley K, Eagle KA, Goto S, et al; REACH Registry Investigators. \u03b2-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. <i>JAMA<\/i> 2012; 308: 1340\u20131349.","DOI":"10.1001\/jama.2012.12559"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Andersson C, Shilane D, Go AS, Chang TI, Kazi D, Solomon MD, et al. \u03b2-blocker therapy and cardiac events among patients with newly diagnosed coronary heart disease. <i>J Am Coll Cardiol<\/i> 2014; 64: 247\u2013252.","DOI":"10.1016\/j.jacc.2014.04.042"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Steg PG, De Silva R. Beta-blockers in asymptomatic coronary artery disease: No benefit or no evidence? <i>J Am Coll Cardiol<\/i> 2014; 64: 253\u2013255.","DOI":"10.1016\/j.jacc.2014.04.043"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Sorbets E, Labreuche J, Simon T, Delorme L, Danchin N, Amarenco P, et al. Renin-angiotensin system antagonists and clinical outcomes in stable coronary artery disease without heart failure. <i>Eur Heart J<\/i> 2014; 35: 1760\u20131768.","DOI":"10.1093\/eurheartj\/ehu078"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al; IMPROVE-IT Investigators. Ezetimibe added to statin therapy after acute coronary syndromes. <i>N Engl J Med<\/i> 2015; 372: 2387\u20132397.","DOI":"10.1056\/NEJMoa1410489"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Cholesterol Treatment Trialists\u2019 (CTT) Collaboration;Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170,000 participants in 26 randomised trials. <i>Lancet<\/i> 2010; 376: 1670\u20131681.","DOI":"10.1016\/S0140-6736(10)61350-5"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Giugliano RP, Sabatine MS. Are PCSK9 inhibitors the next breakthrough in the cardiovascular field? <i>J Am Coll Cardiol<\/i> 2015; 65: 2638\u20132651.","DOI":"10.1016\/j.jacc.2015.05.001"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, et al; ODYSSEY LONG TERM Investigators. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. <i>N Engl J Med<\/i> 2015; 372: 1489\u20131499.","DOI":"10.1056\/NEJMoa1501031"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Sabatine MS, Giugliano RP, Keech A, Honarpour N, Wang H, Liu T, et al. Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial. <i>Am Heart J<\/i> 2016; 173: 94\u2013101.","DOI":"10.1016\/j.ahj.2015.11.015"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Schwartz GG, Bessac L, Berdan LG, Bhatt DL, Bittner V, Diaz R, et al. Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: Rationale and design of the ODYSSEY outcomes trial. <i>Am Heart J<\/i> 2014; 168: 682\u2013689.","DOI":"10.1016\/j.ahj.2014.07.028"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Nicholls SJ, Tuzcu EM, Sipahi I, Grasso AW, Schoenhagen P, Hu T, et al. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. <i>JAMA<\/i> 2007; 297: 499\u2013508.","DOI":"10.1001\/jama.297.5.499"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Fitzgerald K, Frank-Kamenetsky M, Shulga-Morskaya S, Liebow A, Bettencourt BR, Sutherland JE, et al. Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin\/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: A randomised, single-blind, placebo-controlled, phase 1 trial. <i>Lancet<\/i> 2014; 383: 60\u201368.","DOI":"10.1016\/S0140-6736(13)61914-5"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Rohatgi A, Khera A, Berry JD, Givens EG, Ayers CR, Wedin KE, et al. HDL cholesterol efflux capacity and incident cardiovascular events. <i>N Engl J Med<\/i> 2014; 371: 2383\u20132393.","DOI":"10.1056\/NEJMoa1409065"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Shaw JA, Bobik A, Murphy A, Kanellakis P, Blombery P, Mukhamedova N, et al. Infusion of reconstituted high-density lipoprotein leads to acute changes in human atherosclerotic plaque. <i>Circ Res<\/i> 2008; 103: 1084\u20131091.","DOI":"10.1161\/CIRCRESAHA.108.182063"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Ridker PM, L\u00fcscher TF. Anti-inflammatory therapies for cardiovascular disease. <i>Eur Heart J<\/i> 2014; 35: 1782\u20131791.","DOI":"10.1093\/eurheartj\/ehu203"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Smeeth L, Thomas SL, Hall AJ, Hubbard R, Farrington P, Vallance P. Risk of myocardial infarction and stroke after acute infection or vaccination. <i>N Engl J Med<\/i> 2004; 351: 2611\u20132618.","DOI":"10.1056\/NEJMoa041747"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Nidorf SM, Eikelboom JW, Budgeon CA, Thompson PL. Low-dose colchicine for secondary prevention of cardiovascular disease. <i>J Am Coll Cardiol<\/i> 2013; 61: 404\u2013410.","DOI":"10.1016\/j.jacc.2012.10.027"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Ridker PM, Thuren T, Zalewski A, Libby P. Interleukin-1\u03b2 inhibition and the prevention of recurrent cardiovascular events: Rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). <i>Am Heart J<\/i> 2011; 162: 597\u2013605.","DOI":"10.1016\/j.ahj.2011.06.012"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Everett BM, Pradhan AD, Solomon DH, Paynter N, Macfadyen J, Zaharris E, et al. Rationale and design of the Cardiovascular Inflammation Reduction Trial: A test of the inflammatory hypothesis of atherothrombosis. <i>Am Heart J<\/i> 2013; 166: 199\u2013207.","DOI":"10.1016\/j.ahj.2013.03.018"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Antithrombotic Trialists\u2019 (ATT) Collaboration;Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, et al. Aspirin in the primary and secondary prevention of vascular disease: Collaborative meta-analysis of individual participant data from randomised trials. <i>Lancet<\/i> 2009; 373: 1849\u20131860.","DOI":"10.1016\/S0140-6736(09)60503-1"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Wiviott SD, Steg PG. Clinical evidence for oral antiplatelet therapy in acute coronary syndromes. <i>Lancet<\/i> 2015; 386: 292\u2013302.","DOI":"10.1016\/S0140-6736(15)60213-6"},{"key":"27","doi-asserted-by":"publisher","unstructured":"27. Yeh RW, Secemsky EA, Kereiakes DJ, Normand ST, Gershlick AH, Cohen DJ, et al; DAPT Study Investigators. Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention. <i>JAMA<\/i>2016 March 29, doi:10.1001\/jama.2016.3775.","DOI":"10.1001\/jama.2016.3775"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Steg PG, Bhatt DL, Hamm CW, Stone GW, Gibson CM, Mahaffey KW, et al; CHAMPION Investigators. Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: A pooled analysis of patient-level data. <i>Lancet<\/i> 2013; 382: 1981\u20131992.","DOI":"10.1016\/S0140-6736(13)61615-3"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Pollack CV Jr, Reilly PA, Eikelboom J, Glund S, Verhamme P, Bernstein RA, et al. Idarucizumab for dabigatran reversal. <i>N Engl J Med<\/i> 2015; 373: 511\u2013520.","DOI":"10.1056\/NEJMoa1502000"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Ellis SG, Kereiakes DJ, Metzger DC, Caputo RP, Rizik DG, Teirstein PS, et al; ABSORB III Investigators. Everolimus-eluting bioresorbable scaffolds for coronary artery disease. <i>N Engl J Med<\/i> 2015; 373: 1905\u20131915.","DOI":"10.1056\/NEJMoa1509038"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Byrne RA. Bioresorbable vascular scaffolds: Will promise become reality? <i>N Engl J Med<\/i> 2015; 373: 1969\u20131971.","DOI":"10.1056\/NEJMe1512331"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Mega JL, Stitziel NO, Smith JG, Chasman DI, Caulfield MJ, Devlin JJ, et al. Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: An analysis of primary and secondary prevention trials. <i>Lancet<\/i> 2015; 385: 2264\u20132271.","DOI":"10.1016\/S0140-6736(14)61730-X"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Roberts R. Genetics of coronary artery disease. <i>Circ Res<\/i> 2014; 114: 1890\u20131903.","DOI":"10.1161\/CIRCRESAHA.114.302692"}],"container-title":["Circulation Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/80\/5\/80_CJ-16-0266\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,6]],"date-time":"2019-09-06T10:37:54Z","timestamp":1567766274000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/80\/5\/80_CJ-16-0266\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1253\/circj.cj-16-0266","relation":{},"ISSN":["1346-9843","1347-4820"],"issn-type":[{"value":"1346-9843","type":"print"},{"value":"1347-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016]]}}}